Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial) by Galadanci, NA et al.
Feasibility trial for primary stroke 
prevention in children with sickle cell 
anemia in Nigeria (SPIN trial) 
 
Najibah A. Galadanci, Shehu Umar Abdullahi, Leah D. Vance, Abdulkadir 
Musa Tabari, Shehi Ali, Raymond Belonwu, Auwal Salihu, Aisha Amal 
Galadanci, Binta Wudil Jibir, Halima Bello-Manga, Kathleen Neville, Fenella 
J. Kirkham, Yu Shyr, Sharon Phillips, Brittany V. Covert, Adetola A. Kassim, 
Lori C. Jordan, Muktar H. Aliyu, Michael R. DeBaun 
Correspondence Michael R. DeBaun, Vanderbilt-Meharry Center of Excellence in Sickle Cell 
Disease, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 
Children's Way, Room 11206 DOT, Nashville, TN 37232-9000. Email: 
m.debaun@vanderbilt.edu 
 
 Funding information National Institute of Neurological Disorders and Stroke of the 
National Institutes of Health, Grant/Award Number: 1R21NS080639-01; Doris Duke 
Charitable Foundation, Burroughs Wellcome Foundation, Phillips Family Donation, 
Aaron Ardoin Foundation for Sickle Cell Anemia, New York University School of 
Medicine Cardiovascular Research Training Institute (CaRT), Grant/Award Number: 
5D43TW009140-03; J.C. Peterson, MD, endowed chair funds from Vanderbilt 
University School of Medicine. The REDcap tool used for this study is supported by 
NCATS/NIH UL1 TR000445 (Vanderbilt Institute for Clinical and Translational 
Research). 
  
Abstract 
The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-
based guidelines for primary stroke prevention are lacking. In Kano, Nigeria, we conducted a 
feasibility trial to determine the acceptability of hydroxyurea therapy for primary stroke 
prevention in children with abnormal transcranial Doppler (TCD) measurements. Children 
with SCA and abnormal non-imaging TCD measurements (≥200 cm/s) received moderate 
fixed-dose hydroxyurea therapy (∼20 mg/kg/day). A comparison group of children with TCD 
measurements <200 cm/s was followed prospectively. Approximately 88% (330 of 375) of 
families agreed to be screened, while 87% (29 of 33) of those with abnormal TCD 
measurements, enrolled in the trial. No participant elected to withdraw from the trial. The 
average mean corpuscular volume increased from 85.7 fl at baseline to 95.5 fl at 24 months 
(not all of the children who crossed over had a 24 month visit), demonstrating adherence to 
hydroxyurea. The comparison group consisted of initially 210 children, of which four 
developed abnormal TCD measurements, and were started on hydroxyurea. None of the 
monthly research visits were missed (n = total 603 visits). Two and 10 deaths occurred in the 
treatment and comparison groups, with mortality rates of 2.69 and 1.81 per 100 patient-years, 
respectively (P = .67). Our results provide strong evidence, for high family recruitment, 
retention, and adherence rates, to undertake the first randomized controlled trial with 
hydroxyurea therapy for primary stroke prevention in children with SCA living in Africa. 
  
INTRODUCTION 
One of the most feared and devastating complications for children with sickle cell anemia 
(SCA) and their family is a stroke. In children with SCA in high-income countries, strokes 
are now mostly preventable. Abnormal transcranial Doppler (TCD) ultrasound screening 
coupled with regular blood transfusion therapy has resulted in a significant drop in the rate of 
strokes.[1, 2] In one tertiary care center in the United States, the stroke incidence rate 
dropped by approximately 10-fold (from 0.67 to 0.06 strokes per 100 patient-years) after 
initiation of routine TCD screening, with regular blood transfusion therapy for those with 
abnormal TCD measurements.[2] 
Unfortunately, in Africa, no systematic approach has been undertaken to prevent strokes in 
children with SCA. Nigeria is the country with the largest population of SCA in the world 
(approximately 150,000 births of children with SCA per year),[3] compared to the United 
States (approximately 1,200 births of children with SCA per year).[4, 5] Major obstacles for 
primary stroke prevention in Nigeria include, but are not limited to: the lack of access to TCD 
equipment and inadequate training of staff in detecting abnormal TCD measurements. 
Possibly the greatest challenge to primary stroke prevention in Africa is the inability to 
replicate the standard of care for primary stroke prevention present in high-income countries, 
specifically regular blood transfusion therapy for at least a year for those with abnormal TCD 
measurements.[6] Regular blood transfusion therapy for stroke prevention is not accepted as 
an option for most parents of children in Nigeria with SCA because of concerns about cost, 
safety of blood transfusion[7] and limited blood supply. 
Given that regular blood transfusion therapy is not a viable option for primary stroke 
prevention for children living in Africa, we conducted a single-arm feasibility trial to 
determine the acceptability of moderate fixed-dose hydroxyurea (∼ 20 mg/kg/day) for 
primary stroke prevention in Nigerian children with SCA (NCT01801423; grant number 
1R21NS080639). We tested the primary hypothesis that moderate fixed-dose hydroxyurea 
therapy is a feasible intervention for children with SCA and TCD measurements ≥200 cm/s 
(non-imaging technique). We also established strategies for hydroxyurea toxicity monitoring 
in and creating stroke prevention teams in Nigeria beyond the setting of the clinical trial. 
METHODS 
Study design 
Ethical approval for the study was obtained from the Institutional Review Boards (IRB) of 
Aminu Kano Teaching Hospital (AKTH) and Vanderbilt University Medical Center. 
Regulatory approval was provided by the National Agency for Food and Drug Administration 
and Control (NAFDAC) in Nigeria. Written informed consent and assent were obtained prior 
to screening. The single-arm and single-site feasibility trial was opened for enrollment in 
April 2013, approximately six months after receipt of funding. Enrollment was completed in 
October 2014. The trial was conducted at the pediatric sickle cell disease (SCD) clinic of 
AKTH located in Kano, Nigeria. From April 2013 to October 2014, we performed screening 
procedures on all consented children with SCA to determine those eligible for study therapy. 
The data were locked for analysis in November 2016. 
The inclusion criteria for the moderate fixed-dose hydroxyurea therapy included: (1) 
confirmed diagnosis of HbSS or HbSB0, referred to as SCA; (2) two independent TCD time-
averaged maximum mean velocity (TAMV) readings of ≥200 cm/s in the middle cerebral 
artery (MCA) using the non-imaging technique, based on validated assessments conducted by 
two study radiologists or a single measurement >220 cm/s; (3) age 5 to 12 years (including 
the peak age of onset of strokes in SCA, which is approximately 6 years)[8]; (4) ability to 
swallow an empty (similar size to study therapy) pill capsule prior to treatment; and (5) 
acceptance of hydroxyurea therapy with minimum follow-up period of 12 months on the 
study therapy. All eligible participants for the trial were offered regular blood transfusion 
therapy for primary stroke prevention. 
The exclusion criteria included: (1) prior history of overt stroke, or concern for moderate to 
severe neurological deficit based on a positive validated “Ten questions” screening[9, 10]; (2) 
other significant organ system dysfunction (any contraindication to hydroxyurea therapy); (3) 
history of seizures or diagnosis of epilepsy; (4) prior placement on regular blood transfusion 
or hydroxyurea therapy; (5) significant cytopenias (absolute neutrophil count < 1.5 × 109/L, 
platelets < 150 × 109/L). We excluded children less than five years of age due to the high 
mortality rate as well as malarial and bacterial infections seen in this age group in 
Nigeria.[11-14] 
The comparison group consisted of individuals who signed the informed consent, had TCD 
measurements <200 cm/s in the MCA, and who agreed to be followed prospectively. The 
comparison group was followed with at least one standard care visit per year with planned at 
least monthly interim telephone calls to assess status. Participants in the comparison group 
could crossover to the therapy group, if during routine care, the TCD measurements were 
≥200 cm/s in the MCA. The follow-up time for the comparison group is counted up until the 
date a participant crossed over to therapy, last day of follow-up or death, whichever came 
first. 
Certification in TCD ultrasound scans technique and neurology examination 
Initially, two Nigerian radiologists recruited for the trial were trained and certified after 
demonstrating reproducibility in assessment of velocity in the MCA with an experienced 
ultrasonographer in the United Kingdom (who has been teaching nonimaging TCD procedure 
for two decades). The two on-site radiologists on the trial were certified only in assessing 
velocity in the MCA using a nonimaging TCD machine (Acuson Sequola, Siemens 
Healthcare GmbH, Germany). For the TCD training, we used volunteers both with and 
without SCA, including several with prior abnormal TCD values. After completion of 
training, one of the two trial radiologists was responsible for training and certifying three 
nonradiology Nigerian physicians (medical officers) to determine TCD measurements in the 
MCA only. For the trial-certified radiologist (trainer), we determined the intra-observer 
coefficient of variation by repeating the TCD measurements in the same participant on the 
right and left MCAs in study participants within 3 hours. Spearman's rank correlation (r) was 
performed on the two measurements made by the trainer on the right and left side. The 
minimum acceptable correlation for the trainer's two measurements on each side was set at 
0.90, with an expected lower bound correlation between the trainer and trainee of 0.76 (85% 
of the trainer's correlation in the same individual performed only hours apart). 
The sample size for the TCD training for the trainees, as compared to the trainer, was 
calculated using Spearman's rank correlation. Sample sizes of 42 and 31 paired measurements 
between the trainer and each trainee were associated with a power of 90% and 80%, 
respectively, based on the correlation between the trainer and trainee exceeding the lower 
bound of 0.76 (this is 85% of the trainer?s correlation as the minimum acceptable correlation 
threshold). Based on these sample size calculations, we aimed for each trainee (medical 
officer) and the trainer to have at least 40 paired TCD evaluations. All research physicians 
were trained and certified on the Pediatric NIH Stroke Scale (PedNIHSS), a validated, 
standardized neurological examination that was used for the study.[15] Each TCD-certified 
medical officer performed a minimum of 10 neurological examinations in children, which 
were verified by two experienced pediatric neurologists (L. Jordan, F. Kirkham). The SCA 
Primary Stroke Prevention Team consisted of a pediatrician, ultrasonographer (medical 
officer) and pediatric nurse. The research team was larger, but the team interacted with the 
children and family daily. 
Measurements of feasibility of hydroxyurea therapy required for a phase III 
trial 
Feasibility of the trial was measured with three outcomes: recruitment, retention, and 
adherence rates to hydroxyurea therapy. Recruitment rate was measured based on the 
proportion of participants approached that signed informed consent divided by the number of 
participants approached. Retention rate was measured based on the proportion of participants 
that elected to remain in the trial. Adherence rate was measured directly by an increase in 
mean corpuscular volume (MCV) (with an expected increase of at least 10 femtoliter (fL), 
and indirectly by the modified Morisky Medication Adherence Scale score (MMAS-8).[16-
18] The MMAS-8 was previously validated for assessment of hydroxyurea adherence in 
children with SCA.[16] The MMAS-8 is scored as follow: high adherence (8 points), average 
adherence (6 to 7 points), and poor adherence (0 to 5 points). 
Sample size for feasibility trial 
After funding of the trial, the AKTH IRB rejected a randomized controlled trial with a 
treatment and placebo arm of 40 abnormal TCD measurements; consequently, we elected to 
enroll 25 participants with abnormal TCD measurements to receive fixed-dose hydroxyurea 
therapy (treatment group) and 210 participants with TCD measurements < 200 cm/s to be 
followed prospectively (comparison group). The final sample size was based on budgetary 
restraints. 
Safety monitoring and evaluation for participants receiving moderate fixed-
dose hydroxyurea therapy 
Monitoring for unanticipated adverse effects was performed two weeks after starting 
hydroxyurea therapy for all participants; thereafter, monthly. A missed follow-up visit was 
defined as not being evaluated within two weeks of the scheduled monthly visit. An interval 
history of medical events and laboratory values were obtained monthly during the planned 
research visits for each participant. We developed a safety laboratory algorithm based on 
laboratory values in children with SCA followed at AKTH 
(https://medschool.vanderbilt.edu/cqs/spin-resources) We also interviewed parents during 
monthly follow-up visits for participants receiving hydroxyurea therapy for assessment of 
indicators of stroke and adherence. Participants on hydroxyurea therapy were monitored with 
scheduled research visits monthly for cytopenias. We defined an adverse event as adverse 
reactions that are expected complications in children with SCA (including pain, acute chest 
syndrome, priapism, sepsis, splenic sequestration, hospitalization, and blood transfusion 
therapy). We defined severe adverse events as those leading to prolonged hospitalization 
beyond seven days, admission into the intensive care unit, near death, or death. We used the 
Common Toxicity Criteria for Adverse Events.[19] 
Evaluation for participants in the comparison group 
On an ongoing basis (typically monthly), we reviewed the hospitalization records for 
individuals in the comparison group and contacted the parents with a goal of at least monthly 
to determine if their child was hospitalized, and if so, for what reason. We recorded an annual 
visit and TCD assessment (as standard care) for participants in the comparison group. When 
possible, we sought medical records to better characterize the reason for hospitalization and 
whether the child was still alive (and if not, the cause of death). 
Baseline immunization status in participants screened to participate in trial 
Immunization cards, if available, were confirmed for immunization status for Haemophilus 
influenzae type b (Hib vaccine) and pneumococcal conjugate vaccine (PCV-13 vaccine). 
Otherwise, medical records or parent recall were recorded. Vaccination coverage for Hib and 
PCV-13 was defined only in cases in which the written record of the immunization matched 
the oral history. Complete vaccination was defined as three documented doses for Hib 
vaccination and at least one documented dose of PCV-13. 
Statistical analysis 
Study data were collected and managed using Research Electronic Data Capture (REDCap) 
electronic data capture tools hosted at Vanderbilt University Medical Center.[35] REDCap is 
a secure, web-based application designed to support data capture for research studies, 
providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data 
manipulation and export procedures; 3) automated export procedures for seamless data 
downloads to common statistical packages; and 4) procedures for importing data from 
external sources. We summarized descriptive statistics using median and interquartile range 
(IQR) for continuous data and percentages for categorical data. The comparison of baseline 
characteristics between the study and comparison groups was performed using Wilcoxon 
rank sum test for continuous variables and Pearson's Chi-Square test for categorical variables. 
Paired Wilcoxon rank sum tests were performed to examine the change in laboratory values 
from baseline to 3 months and from baseline to 12 and 24 months. All tests used a 2-tailed 
probability, with P-values < .05 considered statistically significant. All analyzes were 
performed using R version 3.2.3. 
RESULTS 
Demographics of treatment and comparison group 
A total of 25 participants were initially enrolled in the treatment group and received moderate 
fixed-dose hydroxyurea therapy (range: 16.5 to 23.5 mg/kg/day, based on the weight of the 
child and the capsule size). A total of 210 participants were enrolled in the comparison group. 
The median ages of the study participants in the treatment and comparison group were 8.2 
and 6.8 years, respectively. No statistically significant differences were observed in age, sex, 
ethnicity, height, and weight between the treatment and comparison groups, Table 1. The 
median for follow-up for the treatment and comparison group was 2.1 years and 2.1 years, 
respectively. 
Good reproducibility in trainer and successful TCD training in 
nonradiologists 
The trainer, a board certified Nigerian radiologist, demonstrated reasonable ability to 
reproduce their results with paired examination in the same participant. The trainer's 
coefficient of variation obtained in 21 participants for the right and left MCAs were 7.6% and 
12.0%, respectively, in the same participant and with the second evaluation occurring within 
three hours after the first evaluation. 
The correlation coefficient between the trainee and trainer for the right and left MCA was 
high. In the right MCA, each trainee had a correlation coefficient greater than 0.90 (n = 40). 
For the left MCA, the correlation coefficient for each pair was greater than 0.83 for all three 
trainees (n = 40). All trainees had correlation coefficients greater than minimally accepted 
threshold of 0.76. 
Enrollment and retention rates were high 
A total of 375 families were approached to be screened for abnormal TCD measurements, of 
which 88% (330 of 375) consented for screening, 9% (29 of 323) had abnormal TCD 
measurements and were eligible for therapy. A total of 86% (25 of 29) participated in the trial 
and received hydroxyurea therapy; inclusive of four participants in the comparison group that 
crossed over to the therapy group. A total of 294 parents of children were approached to be in 
the comparison group, of which 71% (210 of 294) consented to enroll, Figure 1. None of the 
families of children with abnormal TCD measurements (n = 29) agreed to regular blood 
transfusion therapy for primary stroke prevention. A total of 10 participants signed the 
informed consent, but did not have any follow-up in the sickle cell disease clinic, for a total 
of 200 participants remaining in the comparison group. After cross-over of four participants 
with elevated TCD measurements, leaving a total of 196 participants in the comparison group 
were actively followed, Figure 2. As per protocol, all participants in the treatment group were 
expected to attend monthly research visits for interval history, physical examination, and 
laboratory surveillance for assessment of hydroxyurea toxicity. None of the scheduled visits 
were missed (n = total 603 visits). None of the participants in the treatment group withdrew 
voluntarily from the trial (retention rate 100%). One participant was administratively 
withdrawn from the study due to development of progressive renal failure after enrolling in 
the trial. During follow-up visits, four participants in the comparison group converted to 
abnormal TCD velocities at 8, 10, 15, and 19 months after enrollment, respectively. 
Figure 1.  
SPIN Trial Participants Recruitment Flow Diagram. Screening, Comparison and Treatment 
Group, and Follow-up. The screening and allocation to treatment group extended from April 
2013 through November 2014. Participants may have had more than one reason for exclusion 
or withdrawal from the study. For participants who were lost to follow-up, data that had 
accrued before withdrawal were used in the analysis. *One participant died after 
administratively withdrawn from the trial because of progressive renal failure unrelated to 
administration of hydroxyurea 
Adherence rates to hydroxyurea therapy and monthly research visits were 
high 
Both direct laboratory measures and the parents’ assessments of adherence were high. An 
increase in MCV by at least 10 fL was observed in 20 of 27 participants (not all participants 
that crossed over reached 24 month evaluations), with the mean MCV increasing from 85 fL 
at baseline to 96 fL, 98 fL, and 96 fL at 3, 12, and 24 months, respectively. In three 
participants without an increase of at least 10 fL in the MCV values; one participant had an 
increase in their baseline hemoglobin of 1.9 g/dl, 12 months after the start of hydroxyrea, and 
the other two had baseline MCV measurements of 97 fL. There was an increase in the mean 
hemoglobin F level from 8.8% at month 1 to 11.6%, 14.1%, and 14.3% at 3, 12, and 24 
months, respectively. Parental report of adherence based on the modified MMAS-8 was high, 
with 100% of participants demonstrating average to high adherence to hydroxyurea therapy 
with scores >6 points. The mean Morisky score for the feasibility trial was 6.8, with 10th 
percentile of 6.6, 50th percentile of 6.9, and 80th percentile of 7.1. The mean MMAS-8 for 
each child ranged from 6.0 to 7.2. 
Low immunization rates and high chemoprophylaxis coverage among 
participants 
A low percentage of screened participants had complete, or any, immunization coverage 
based on PCV-13 and Hib rates of immunization. Coverage for PCV-13 was 12.9%, 1.2%, 
and 0.3% for the 1st, 2nd, and 3rd doses, respectively. Coverage for Hib was 37.5%, 35.4%, 
and 32.6% for the 1st, 2nd, and 3rd doses, respectively. A total of 8.0% (26 of 325) of those 
screened, with available immunization records, had not received any routine immunizations. 
In contrast, a majority of participants received chemoprophylaxis including anti-malarial 
medications and penicillin V. The coverage for anti-malarial prophylaxis with daily oral 
proguanil was 98.7% (321 of 325), and pneumococcal prophylaxis with daily oral penicillin 
V was 78.5% (255 of 325). 
Early results indicate that moderate fixed-dose hydroxyurea therapy is safe 
Serious adverse events and adverse events occurred with similar rates in both the treatment 
and comparison group, Table 2. A total of 12 deaths occurred: two deaths in the treatment 
group (2.69 per 100 patient-years based on intention-to-treat analysis) and 10 deaths in the 
comparison group (1.81 per 100 patient-years) (P = .67). The first participant in the treatment 
group that died was on hydroxyurea therapy for 18 months with a dose of 23.5 mg/kg/day. He 
was hospitalized for infection with severe anemia, subsequently developed seizures, and was 
treated with broad-spectrum antibiotics, antimalarial therapy, and exchange transfusion. The 
second participant, initially in the treatment group, developed progressive renal disease of 
unknown etiology with an initial creatinine of 112 µmol/L. The creatinine level gradually 
increased to >200 µmol/L until visit 17, when he was withdrawn from the study, and 
hydroxyurea was continued on compassionate basis to decrease the likelihood of acute vaso-
occlusive events. The second participant died one month after being administratively 
withdrawn from the trial. Of the participants who died, none received PCV-13 vaccinations 
and only two were vaccinated against Hib. At the time of death, all participants were 
prescribed malarial prophylaxis, and 11 of 12 participants were prescribed penicillin 
prophylaxis, Table 3. One stroke occurred in a participant in the comparison group, with 
TCD measurements of 183 cm/s in the right MCA and 116 cm/s in the left MCA, 10 months 
prior to the stroke. 
Overall, no laboratory evidence of severe myelosuppression was recorded in any of the 
participants during the monthly laboratory assessments. Out of 712 complete blood cell 
counts, the number of times when platelet count <80 × 109/L and absolute neutrophil count 
<1.0 × 109/L was two and four, respectively; and neither of the values were persistently low 
after a repeat evaluation, with no dose adjustment. Approximately 4.6% (33 of 712) of all 
hemoglobin measurements were <6 g/dL. Only two children had at least two consecutive 
hemoglobin levels of <6 g/dL:, one with progressive renal failure and ultimately died because 
of renal failure and the second child with chronic hypersplenism. 
4 DISCUSSION 
Strokes in children with SCA result in immeasurable suffering, disability, and premature 
death.[20] Despite the majority of children with SCA being born in Africa[3, 4] and the 
evidence that interventions are available to help prevent strokes,[6, 21] no systematic attempt 
has been undertaken to prevent strokes in this continent. To address this large gap in medical 
knowledge and humanitarian need, we designed and implemented the SPIN (Stroke 
Prevention in Nigeria) trial. 
Completion of the SPIN Trial had three important findings. First, our results demonstrated 
that parents of children with SCA in Nigeria have at least similar, if not higher, rates of 
successful recruitment, retention, and adherence to study medication when compared to 
comparable trials in high-income countries.[22-24] Second, we provided evidence that 
creating SCA Primary Stroke Prevention Teams, consisting of a skilled TCD ultra 
sonographer, pediatrician, and nurse, is feasible in Africa. Third, we demonstrated for 
children with SCA living in Africa, in the absence of a completed randomized controlled 
clinical trial (RCT) for primary stroke prevention, moderate fixed-dose hydroxyurea therapy 
(∼20 mg/kg/day) is a reasonable strategy to undertake with monthly clinical and laboratory 
surveillance. 
In Africa, shortages of TCD machines and health care providers with the requisite skills to 
perform TCD testing (such as radiologists) are major barriers to implementing routine TCD 
examinations. Obtaining accurate TCD measurements with certified ultrasonographers 
(physicians or non-physicians), who were not radiologists, was the rate-limiting step for our 
trial. To our knowledge, this is the first effort to establish a TCD training program in 
nonradiology physicians in Africa. Local practices at our study sites in Nigeria, prevented 
non-physicians from learning TCD techniques. Our TCD training approach was successful 
with the inter-observer variability coefficient >0.8 among all trainees when compared to the 
trainer. Ultimately, given the large number of children with SCA, when primary stroke 
prevention becomes a priority in Africa, radiologists will be needed to certify non-physician 
ultrasonographers. 
Previous studies demonstrated intra- and inter-observer variability were important sources of 
measurement error in TCD assessments.[25, 26] In addition to observer variability, poorly 
defined participant TCD variability (or intra-participant standard deviation) must be 
considered when interpreting TCD measurements. In children with SCA with two TCD 
measurements evaluated less than 6 months apart, the 95% confidence limit for change in 
steady state TCD measurement was 29 cm/s.[27] In the recently completed TCD with 
Transfusion Changing to Hydroxyurea (TWITCH) trial, for children receiving blood 
transfusion therapy with at least 6 measurements, the average within participant variation was 
between 10.2 and 12.3 cm/s.[28] To minimize the contribution of participant TCD variability 
in assessment of intra-observer variability of the skilled radiologist (trainer), we elected for 
the trainer to repeat the TCD measurement in the same participant within a 3-hour time 
window. Our results demonstrated that even in the best of circumstances, there will be a 7-
12% variability in the assessment of TCD when performed by a skilled radiologist in the 
same child on the same day. Together, these data validate our approach of utilizing entry 
criteria of two independent TCD values ≥200 cm/s or one value >220 cm/s, preferably 
performed by a second certified ultrasonographer. 
Prior to starting the trial, we were uncertain of the appropriate hydroxyurea treatment dose 
(fixed-dose ∼10 mg/kg (low) versus fixed-dose ∼20 mg/kg (moderate), or maximum 
tolerated dose). However, based on the hydroxycarbamide in very young children with SCA 
trial (BABY HUG) where participants were randomly allocated to moderate dose 
hydroxyurea therapy or placebo,[29] a moderate dose of hydroxyurea was not associated with 
rates of increased cytopenias. The rate of significant cytopenia is no different than in children 
not on hydroxyurea.[29] Further, approximately 80% of the children in the trial dropped their 
TCD measurements to <200 cm/s, approximately three months after starting hydroxyurea 
therapy.[30, 31] In comparison, among participants in the Optimizing Primary Stroke 
Prevention in Sickle Cell Anemia (STOP 2) trial, after initiating regular blood transfusion 
therapy, 52% of the participants had normal TCD measurements after a mean of 4.3 
months.[32] These data, coupled with those from the recently completed TWiTCH Trial 
demonstrating that hydroxyurea therapy was noninferior to blood transfusion for primary 
stroke prevention in children with abnormal TCD measurements, and no evidence of 
magnetic resonance cerebrovascular disease, after a year of regular blood transfusion 
therapy,[6] strongly suggest that moderate fixed-dose hydroxyurea therapy is a reasonable 
starting point for primary stroke prevention in Africa. 
The vaccination rate was lower than anticipated. The inadequate PCV-13 and Hib vaccination 
coverage is most likely due to the considerable out-of-pocket expenses for those vaccines for 
families rather than any lack of counseling on the importance of receiving the vaccines. The 
median annual family income of $5490. The out-of-pocket cost for the one PCV-13 
vaccination is $60 in Kano, Nigeria. Given the increased risk of infection and observed 
mortality rate in children with SCA, we believe expanding efforts to treat African children 
with SCA with hydroxyurea therapy should be coupled with efforts to ensure complete 
vaccination coverage, at least against S. pneumoniae and H. influenzae. 
As anticipated, the feasibility trial has inherent limitations. First, a median follow-up duration 
of just over two years does not fully address the concerns about retention for the phase III 
trial (planned therapy for a minimum of least three years), long-term toxicity of hydroxyurea, 
or whether hydroxyurea therapy has a durable impact on preventing strokes in children with 
abnormal TCD measurements. The third year was planned as a transition year between the 
initial R21 funding and receipt of funding for a phase III randomized controlled trial. As a 
result of funding from the National Institute of Neurological Disorders and Stroke 
(1R01NS094041), we will follow the participants in the current feasibility trial for a mean 
duration of six years. Additionally, with the new funding, the teams will conduct a RCT 
comparing moderate fixed-dose hydroxyurea therapy (∼20 mg/kg/day) to low fixed-dose 
hydroxyurea (∼10 mg/kg/day) therapy for primary stroke prevention in children with SCA. 
Second, the initial interval between obtaining the laboratory values and reviewing them in a 
timely fashion was less than optimal. To address the challenge, we recruited laboratory 
personnel allocated to the trial. We also instituted weekly reviews between the study site and 
coordinating center teams that included a local study monitor whose sole responsibility was 
to review all laboratory values and follow the safety algorithm. Finally, 10 of 12 reported 
deaths in the combined treatment and comparison groups occurred at home, with no further 
examinations performed to determine the cause of death—an intrinsic limitation in attributing 
cause of death in low- and middle-income countries.[33] In addition to these limitations, 
challenges relevant to adhering to regulatory guidelines, study medication, and evaluations 
were described in detail elsewhere.[34] 
Results of our first ever NIH-funded SCA trial in Africa indicate that parents of Nigerian 
children with SCA are willing to participate in a clinical trial and adhere to hydroxyurea 
therapy to prevent strokes. We have provided preliminary evidence a moderate fixed-dose 
hydroxyurea therapy (∼20 mg/kg/day) is well-tolerated and may have efficacy in preventing 
strokes in children with SCA. We have established a practical SCA-specific hydroxyurea 
safety-monitoring algorithm for children with SCA living in Africa. Until the phase III trial is 
completed in Africa (NCT02560935), we recommend formation of SCA Primary Stroke 
Prevention Teams consisting of a certified TCD ultrasonographer, pediatrician, and a nurse, 
for initiating a moderate fixed-dose of hydroxyurea therapy, coupled with monthly laboratory 
and clinical surveillance. 
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Table 1. Baseline demographics and characteristics of all children with sickle cell anemia 
enrolled in in SPIN Trial 
Demographics: 
Treatment 
N = 29b 
Comparison 
N = 206 
P 
value 
Age (years), median (IQR) 6.8 (5.7,9.2) 8.2 (6.3,10.4) 0.053 
Gender (Female), % 52 52 0.94 
Height (cm), median (IQR) 
123.0 (114.0, 
134.0) 
125.5(115.2, 132) 0.47 
Weight (kg), median (IQR) 20.0 (17.0,23.0) 20 (17.0,24.0) 0.60 
Ethnicity (Hausa/Fulani), % 81.5 91.8 0.17 
Tertiary education for parent 
(college/university training), % 
48 79 0.001 
Length of follow-up (years), median (IQR) 2.1 (1.8,2.7) 2.1 (1.9,2.5) 0.44 
Annual incomea     0.24 
<$5000 48% 36%   
≥$5000 52% 64%   
Mean 4183 5395   
Median 4270 6100   
Hydroxyurea dose (mg/kg/day), minimum 
and maximum dose 
19.23 (16.58, 
21.88) 
none   
 
 
 
Table 2. Comparison of incidence rates of hospitalization in the first 36 months between the 
treatment and comparison groups in the SPIN trial 
Indication for 
hospitalization 
Treatment Group (Per 100 
person-years) 
Comparison Group (Per 100 
person-years) 
Acute chest syndrome 0 0.54 
Osteomyelitis 0 0.54 
Infection 6.73 2.18 
Pain 12.12 21.22 
Stroke 0 0.18 
Transfusion 8.08 3.63 
Malaria positive WHOa 9.42 12.15 
Fever 12.12 7.07 
Other 8.08 2.53 
Total 56.54 50.24 
 
  
Table 3. Age, immunization status, chemoprophylaxis status and suspected causes of death 
among SPIN Trial participants. No autopsies were performed, and cause of death was based 
on local pediatrician's impression after review of the medical records 
Subject 
Number 
Age at 
Death 
(Years) 
Influenza 
Type 1 
Vaccine 
Pneumococcal 
Vaccine 
Penicillin 
V 
Palludrine 
Postulated 
cause of death 
Comparison Group 
1 12 YES NO YES YES Severe anemia 
2 7 YES NO YES YES 
Transfusion 
reaction 
3 8 NO NO YES YES Malaria 
4 6 NO NO YES YES Severe anemia 
5 10 NO YES YES YES Septicemia 
6 12 YES NO NO YES Severe anemia 
7 5 NO NO YES YES Malaria 
8 11 YES NO YES YES Malaria 
9 10 YES NO YES YES Severe VOC 
10 8 NO NO YES YES Severe VOC 
Treatment Group 
1 7 NO YES YES YES 
Septicemia and 
severe anemia 
2 10 NO NO YES YES Renal disease 
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